THE SELECTIVITY AND SPECIFICITY OF THE ACTIONS OF THE LIPIDO-STEROLIC EXTRACT OF SERENOA REPENS (PERMIXON??) ON THE PROSTATE
- 1 September 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 164 (6) , 876-881
- https://doi.org/10.1097/00005392-200009010-00065
Abstract
To investigate the effects of the phytotherapeutic agent, Permixon(R), on primary cultures of fibroblast and epithelial cells from the prostate, epididymis, testes, kidney, skin and breast and to determine the selectivity and specificity of the action of the drug. All primary cultures were examined by electron microscopy before and following treatment with Permixon(R) (10 microg./ml.). In addition the apoptotic index was assessed by flow cytometry employing propidium iodide as a fluorophore. The impact of the drug on 5alpha-reductase (5alphaR) isoenzymes was also tested utilizing a pH specific assay. There were changes in the morphology of prostate cells after treatment including accumulation of lipid in the cytoplasm and damage to the nuclear and mitochondrial membranes; no similar changes were observed in other cells. Permixon(R) increased the apoptotic index for prostate epithelial cells by 35% and 12% in the prostate stromal/fibroblast. A lesser apoptotic effect was demonstrated in skin fibroblast (3%) whereas none of the other primary cultures showed any increase in apoptosis when compared with the controls. Permixon(R) was also an effective inhibitor of both 5alphaR type I and II isoenzymes in prostate cells, but other cells showed no inhibition of 5alphaR activity following treatment with the plant extract. This investigation demonstrated the selectivity of the action of Permixon(R) for prostate cells. The morphological changes in the prostate are accompanied by an increase in the apoptotic index along with an inhibition in the activity of the nuclear membrane bound 5alphaR isoenzymes. No similar changes were observed in any of the other cells under investigation.Keywords
This publication has 21 references indexed in Scilit:
- Serenoa repens (Permixon ): A 5?-reductase types I and II inhibitor?new evidence in a coculture model of BPHThe Prostate, 1999
- Saw Palmetto Extracts for Treatment of Benign Prostatic HyperplasiaJAMA, 1998
- Effects of long-term treatment withSerenoa repens (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasiaThe Prostate, 1998
- Effect of the Lipidosterolic Extract of Serenoa repens (Permixon®) and Its Major Components on Basic Fibroblast Growth Factor-Induced Proliferation of Cultures of Human Prostate BiopsiesEuropean Urology, 1998
- Serenoa repens (Permixon®)Drugs & Aging, 1996
- Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patientsThe Prostate, 1996
- Phytotherapy for the prostateBritish Journal of Urology, 1996
- Human prostatic steroid 5α-reductase isoforms—A comparative study of selective inhibitorsThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Placebo-Controlled Evaluation of the Efficacy and Tolerability of Permixon® in Benign Prostatic Hyperplasia after Exclusion of Placebo RespondersClinical Drug Investigation, 1995
- Binding of permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostateJournal of Steroid Biochemistry, 1984